The Deal
Tuesday, January 6, 
5:34 pm


Recently in BIO 2007 Convention Category
[Posted on May 9, 2007 - 2:46 PM]
A nightcap at the Four Seasons near Boston Commons last night brought a sighting of San Francisco biotech banker/VC Steven Burrill and his son Joel, an undergrad at Duke University. Both Burrills were still nattily togged, though Burrill the Elder had loosened his tie slightly in deference to the hour. He was positive as always about the biotech IPO...

Continue Reading



[Posted on May 9, 2007 - 11:25 AM]
The big news from the BIO International Convention in Boston Tuesday was the appearance of Massachusetts Gov. Deval Patrick (pictured at left) on the trade show floor to announce a $1 billion state fund for basic science research. The governor’s presence was only noticeable because of the sudden tripling, or what seemed like it, of various uniformed officers sprinkled...

Continue Reading



[Posted on May 8, 2007 - 4:48 PM]
Peel back the glossy façade touting innovation, education and other noble missions, and you start to see what really makes the drug industry go. On a panel today to discuss how to “derisk” the biopharma business model, four CEOs talked cold, hard reality at the BIO International Convention. For example: Don’t even bother forming a startup around a new,...

Continue Reading



[Posted on May 8, 2007 - 12:09 PM]
One recurrent theme at this year’s BIO show: The next target for Big Pharma deals are biotechs, mainly startups, working on molecules that some call “post-antibody” or in more technical speak, “affinity scaffolds.” Two have already been sold: Domantis Ltd. to GlaxoSmithKline plc last December ($454 million), and Avidia Inc. to Amgen Inc. last October ($290 million). These new...

Continue Reading



[Posted on May 7, 2007 - 4:06 PM]
If you can’t go public, what’s a private biotech to do? Dealmaking panelists at the BIO International Convention in Boston kicked that question around Monday morning. Initial public offerings are hard to come by these days, and even when a firm and its backers pull it off, the returns are relatively slim: $40 million to $50 million on average,...

Continue Reading



[Posted on May 7, 2007 - 10:35 AM]
With the BIO conference in Boston expecting 20,000 attendees, many of them from foreign countries, it's easy to overlook the local impact. But the Boston Globe made sure Monday morning to remind its readership, which includes biotech rank and file, researchers and the vast medical work force of the Boston area, that biotech is central to the local economy....

Continue Reading



[Posted on May 4, 2007 - 4:14 PM]
The 2007 BIO International Convention kicks off this weekend in Boston. Nice weather is expected, but it won't match the sunny outlook inside the gigantic Boston Convention & Exhibition Center. All industry trade shows are cheer-fests, of course, but the biotech crowd tends to be particularly self-congratulatory for a few reasons: The industry drives economic growth in high-profile cities,...

Continue Reading
Search


The Tech Confidential Network
The Tech Confidential Network unites the leading voices from around the Internet on the topics of high-tech startups, venture capital and investment exits. Bloggers and publishers that want to expand their readership and monetize their content are encouraged to apply to join the Tech Confidential Network.


Video
 




Windward Ho!

Startups In New York




Syndicate


Fast Search


Categories
Monthly Archives

©Copyright 2008, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.
Sponsored by